Small Cancer Therapy Player Celularity To Provide Research Support For Regeneron's Therapy
Portfolio Pulse from Vandana Singh
Celularity Inc has entered into a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals Inc. The agreement supports the research of Regeneron's allogeneic cell therapy candidates, with an initial focus on a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy. The research will be conducted at Celularity's facility in Florham Park, N.J. Financial terms were not disclosed.
August 29, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celularity Inc has entered into a research collaboration agreement with Regeneron Pharmaceuticals. This could potentially boost Celularity's profile in the biotech industry.
The partnership with Regeneron Pharmaceuticals could potentially boost Celularity's profile in the biotech industry, as it underscores the company's expertise in cell therapy research. This could potentially lead to an increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Regeneron Pharmaceuticals has entered into a research collaboration agreement with Celularity Inc. This could potentially enhance the research and development of Regeneron's allogeneic cell therapy candidates.
The partnership with Celularity Inc could potentially enhance the research and development of Regeneron's allogeneic cell therapy candidates. This could potentially lead to an increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100